The multifarious nature of the damage means treatments for cardiac issues during infection will require tailored approaches.

Images of the players’ hearts showed signs of inflammation consistent with myocarditis, a rare but potentially fatal condition.

A growth factor treatment helps improve cardiac functioning after heart attack in pigs.

Scientists show the approach can kill cells that cause hardening of heart tissue in mice.

Patients in a study of catheter ablation who showed signs of more injury to nerve cells and glia in the heart had fewer symptoms after the treatment.

A trial to test whether so-called c-kit cardiac stem cells, first reported by Piero Anversa, could help patients with chronic heart failure has been halted in light of suspicion surrounding his work.

Harvard and Brigham and Women’s Hospital disavow the work by former faculty member Piero Anversa.

Among 11 infants treated to date, most survived and their heart function improved.

The move by Baylor St. Luke’s Medical Center follows an investigative news report detailing surgical errors and poor research practices.

Scientists correct a mutation in fertilized eggs that causes a severe cardiac disease.

The sinoatrial node is home to multiple pacemakers that keep the heart beating if the main one falters.

These engineered “cells” were made from the secretions and membranes of human mesenchymal stem cells.

The Scientist caught up with cardiac stem cell researcher Mark Sussman to get his thoughts on the American Heart Association’s Scientific Sessions meeting.

Family members with a certain gene variant had unnecessary interventions, highlighting the potential hazards of precision medicine.

Examining the tragedies of several families who each lost multiple children, two teams of researchers reveal a previously unappreciated role for a mitochondrial enzyme.

Given the right environment, cKit+ cells from the mouse heart can develop into new cardiac muscle, according to a study.

A collagen patch seeded with a regenerative protein helps mice and pigs regain cardiac function after a heart attack.

Biotech firm likely to pull the plug after its gene therapy product fails.

Just half of the clinical studies used to gain premarket approval for cardiac devices ever make it into the scientific literature.